Navigation Links
Watson Announces Approval of Nulecit™, the First Generic Alternative to Ferrlecit® for the Treatment of Iron Deficiency Anemia
Date:3/31/2011

MORRISTOWN, N.J., March 31, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it is initiating launch activities of Nulecit™ (sodium ferric gluconate complex in sucrose injection), following FDA approval of GeneraMedix Inc.'s, Abbreviated New Drug Application (ANDA).  Nulecit is the first bioequivalent and therapeutically equivalent alternative to Sanofi-Aventis' Ferrlecit®.  In July 2009 Watson signed a license agreement with GeneraMedix for the exclusive U.S. marketing rights to the product, which will be marketed by Watson's Global Brands business.

Nulecit is approved for the treatment of iron deficiency anemia in adults and children age six years or older undergoing chronic hemodialysis who are receiving supplemental epoetin therapy.  It will offer the convenience and cost savings of administration from a single-dose glass vial, minimizing the need for filter needles or a required test dose.

The branded alternative to Nulecit is currently available only in 5 mL glass ampules that require the tops to be broken off manually before administration, and many protocols require that the product withdrawn with a syringe using a filter needle.

"Watson's Brand sales team is uniquely positioned to effectively maximize the opportunities of this value brand offering, given our experience in marketing injectable iron products," said Fred Wilkinson, Executive Vice President, Global Brands, at Watson.  "Nulecit offers the nephrology community a value brand that is bioequivalent to the innovator product, with the added convenience of packaging in glass vials."

Efficacy with Added ConvenienceIn the bioequivalence study, which involved 240 healthy volunteers, Nulecit and Ferrlecit showed comparable concentrations of total serum iron and transferrin-bound iron over 36 hours.  Each 5 mL gla
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Watson Confirms Favorable Appeals Court Ruling on Generic SEASONIQUE® Patent Challenge
2. Watson Confirms OxyContin® Patent Challenge
3. Watson Confirms District Court Ruling in Generic Fentora® Patent Suit
4. Cephalon Wins FENTORA Patent Suit Against Watson
5. Watson Launches Generic Famvir®
6. Heygood, Orr & Pearson: Los Angeles Court Orders Watson Pharmaceuticals to Produce Documents, Provide Depositions in Fentanyl Patch Death Lawsuit
7. Watson Announces Favorable District Court Ruling in Generic Fentora® Patent Suit
8. Watson Promotes David Buchen, R. Todd Joyce to Executive Vice President
9. Watson to Present at the Barclays 2011 Global Healthcare Conference
10. Watson to Present at the Cowen & Company 31st Annual Healthcare Conference
11. Watson to Present at the 2011 Citi Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... WASHINGTON , Jan. 15, 2014 AARP Foundation today ... support older adults suffering from the severe cold weather that ... are committed to helping those in need; so to support ... dollar-for-dollar contributions up to $250,000, which could mean up to ...
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation (the "Company") ... has received commitments from institutional investors to purchase an ... stock in an at-the-market registered direct offering, led by ... entered into definitive purchase agreements with these investors pursuant ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Radial Strength, FlexibilityHOUSTON, March 18 IDEV Technologies ... and marketing of minimally invasive technologies, announced today ... has approved an investigational device exemption (IDE) for ... a novel stent platform designed for the treatment ...
... March 18 ULURU Inc. (NYSE Alternext: ULU) ... diabetic foot ulcers, and data on the use of ... presented at the annual DFCon Global Meeting in Los ... presented on posters that will be on display during ...
Cached Medicine Technology:U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies' SUPERA Peripheral Stent 2ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009 2ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009 3
(Date:4/17/2014)... 2014-- Colic affects about one in five infants in ... visits during the first several months after birth. Research ... showing promise; however, the April 1, 2014 issue of ... reported on a study, "Probiotics and Infant Colic," concluding ... for infant colic did not reduce crying ...
(Date:4/17/2014)... YORK April 17, 2014 EcoHealth Alliance, a ... health issues, published a comprehensive review today examining the ... Marburg virus. The review calls for improved global surveillance ... as the recent outbreak of Ebola in West Africa ... the countries of Guinea and Liberia. According to ...
(Date:4/17/2014)... by Cesar A. Arias, M.D., Ph.D., at The University ... identified a new superbug that caused a bloodstream infection ... April 17 issue of The New England Journal ... of a class of highly-resistant bacteria known as methicillin-resistant ... major cause of hospital and community-associated infections. The superbug ...
(Date:4/17/2014)... WINSTON-SALEM, N.C. April 17, 2014 Meaningful ... from advanced cancer of the abdomen when treated ... HIPEC, according to a first-of-its-size analysis by physicians ... Forest Baptist has the largest reported, single-center experience ... Edward A. Levine, M.D., and analysis of 20 ...
(Date:4/17/2014)... study has found that India,s shocking rates of suicide ... who are clinging to tiny smallholdings less than ... such as cotton and coffee, that are highly susceptible ... range of previous case studies that point to a ... the ,liberalisation, of the nation,s economy during the 90s. ...
Breaking Medicine News(10 mins):Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:New MRSA superbug emerges in Brazil 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3
... Pressure-Lowering Device to be Available at 1,440 Stores ... April 28 InterCure Ltd., a medical,device company ... (TASE: INCR),today announced that its RESPeRATE(R) hypertension treatment ... into,full-scale retail distribution within the United Kingdom this ...
... motherhood more than doubled in six years among teenage ... published in the May issue of Diabetes Care. ... at gestational diabetes (diabetes that develops during pregnancy, then ... the largest and most diverse study to examine pre-pregnancy ...
... they take, changes in biological clock put many at risk ... Many older adults don,t get enough sleep, which can increase ... disease and diabetes, says the American Academy of Sleep Medicine. ... disturbed sleep and waking up tired every day aren,t a ...
... osteoporosis, , , SATURDAY, April 26 (HealthDay News) -- While ... harmless enough, recent research suggests that those tasty drinks ... enough evidence that high consumption of soda and carbonated ... children, and that,s a real concern and people should ...
... Irvine, Calif., April 25, 2008 -- Advance directives, or ... life-sustaining treatment preferences often change without people being aware ... by UC Irvine researchers Peter Ditto and Elizabeth Loftus. ... in the discrepancy between an individual,s true preferences for ...
... PRINCETON, N.J., April 25 Medarex, Inc.,(Nasdaq: ... BMY ) today announced,that, after meeting with the ... delay the Biologics License Application (BLA) submission for,ipilimumab, ... The FDA has requested additional overall survival (OS),data ...
Cached Medicine News:Health News:InterCure Secures Nationwide Distribution Agreement With Lloyds Pharmacy Group 2Health News:InterCure Secures Nationwide Distribution Agreement With Lloyds Pharmacy Group 3Health News:InterCure Secures Nationwide Distribution Agreement With Lloyds Pharmacy Group 4Health News:Kaiser Permanente study finds diabetes doubling before motherhood 2Health News:Kaiser Permanente study finds diabetes doubling before motherhood 3Health News:Elderly More Likely to Battle Sleep Disorders 2Health News:Cola May Be Bad to the Bones 2Health News:Cola May Be Bad to the Bones 3Health News:Study shows false memories complicate end-of-life treatment decisions 2Health News:Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab 2Health News:Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab 3Health News:Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab 4Health News:Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab 5
Used for the retrieval of stones, stents, or other objects in the urinary tract under direct vision. Retrieval Forceps are designed for use through rigid or flexible endoscopes. Supplied sterile in p...
Used for the retrieval of stones, stents, or other objects in the urinary tract under direct vision. Retrieval Forceps are designed for use through rigid or flexible endoscopes. Supplied sterile in p...
Fulgurating Electrode, 2 F...
ACMI S-Series Cystourethroscope Systems: Precision instruments designed for superior optical recognition, accurate control, and exceptional durability during steam autoclave sterilization....
Medicine Products: